Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The ornithine transcarbamylase deficiency (otc deficiency) market has demonstrated robust growth over the past few years. This market is projected to expand from $0.83 billion in 2024 to reach $0.89 billion by 2025, reflecting a compound annual growth rate (CAGR) of 6.9%. Historically, this expansion has been driven by factors such as enhanced recognition of rare metabolic conditions, advancements in genetic screening and diagnostic methods, the refinement of neonatal screening initiatives, and the increasing adoption of genetic testing for rare diseases.
The market size for ornithine transcarbamylase deficiency (otc deficiency) is anticipated to experience substantial growth over the next few years. It is projected to expand to $1.15 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.8%. This expansion during the forecast period can be attributed to increasing awareness and diagnosis, a rising prevalence of urea cycle disorders, a growing focus on rare disease treatment, an increase in research and clinical trials, and improved patient access to treatments. Significant trends expected during this period include advancements in genetic therapies and gene editing technologies, the development of enzyme replacement therapies, collaborative research initiatives and partnerships, technological improvements in diagnostic tools, and government funding and incentives for orphan drugs.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp
What Are The Main Drivers Boosting The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Industry’s Expansion?
The increasing need for gene therapies is projected to fuel the expansion of the ornithine transcarbamylase deficiency market in the future. Gene therapy is defined as a medical approach or method that involves modifying or adjusting an individual’s genetic makeup to address or avoid illnesses. This demand stems from the increasing occurrence of genetic disorders, given that these conditions frequently present with few available treatments, and gene therapy provides a hopeful strategy to tackle the underlying cause instead of merely controlling symptoms. Ornithine transcarbamylase deficiency exemplifies the potential of gene therapies by rectifying the genetic mutation responsible for disrupting the urea cycle, thereby enabling precise treatment to recover metabolic function and avert the buildup of toxic ammonia. As an illustration, in January 2024, data from the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that in Q4 2023, the count of gene therapies in Phase III saw a 10% increase compared to the prior quarter, representing the initial rise observed since Q3 2022. Consequently, the expanding need for gene therapies is propelling the growth of the ornithine transcarbamylase deficiency market.
What Are The Major Segment Types Covered In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
The ornithine transcarbamylase deficiency (otc deficiency)market covered in this report is segmented –
1) By Product Type: DTX-301; SEL-313; SHP-641; PRX-OTC
2) By Treatment Type: Gene Therapy; Liver Transplant; Dietary Management; Other Treatement Type
3) By Diagnosis: Genetic Testing; Ammonia Level Testing
4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy; Intravenous Dosing Formulation
2) By SEL-313: Immune Tolerance-Inducing Therapy; Enzyme Replacement Therapy (ERT) Combination
3) By SHP-641: Small Molecule Therapy; mRNA-Based Therapeutic Approach
4) By PRX-OTC: Recombinant Enzyme Replacement Therapy; Protein Engineering-Based Therapy
How Are Emerging Market Trends Shaping The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Industry Landscape?
Leading companies operating within the ornithine transcarbamylase deficiency (OTC Deficiency) market are channeling their efforts into creating advanced therapies, particularly mRNA therapeutics, to improve treatment effectiveness and tackle the underlying genetic cause of OTC deficiency. mRNA therapeutics represent a class of treatments that utilize messenger RNA (mRNA) to direct cells to produce specific proteins for therapeutic purposes. These therapies leverage the body’s inherent protein synthesis mechanisms to treat diseases, including genetic disorders, infectious diseases, and cancers. As an illustration, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate intended for ornithine transcarbamylase (OTC) deficiency. This designation is aimed at accelerating the drug’s development and review process, potentially offering benefits such as increased interactions with the FDA and priority review. ARCT-810 is formulated to enable patients with OTC deficiency, a urea cycle disorder, to produce the necessary functional OTC enzyme in their liver cells, thereby addressing the condition’s root cause and potentially enhancing their quality of life.
Which Key Market Players Are Investing In Expansion And Innovation Of Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
Major companies operating in the ornithine transcarbamylase deficiency (OTC deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Industry Expansion?
North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (OTC deficiency) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp
Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2025, By The Business Research Company
5 Alpha Reductase Deficiency Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report
Iron Deficiency Injectable Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Alpha 1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model